EUVIMEDEUVIMED entdecken
Open Access

Opioids and benzodiazepines in oncology: Perspectives on coprescribing and mitigating risks

Amy O'Regan, Jeehye Rose Lee, Cara L McDermott, Harvey Jay Cohen, Jessica S Merlin, Andrea Des Marais, Aaron N Winn, Salimah H Meghani, Devon K Check

Journal of Geriatric Oncology · 2025

DOI: 10.1016/j.jgo.2024.102172 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Geriatric Oncology, 2025. Verfasst von Amy O'Regan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. Hauptthemen laut MEDLINE: Benzodiazepines, Analgesics, Opioid, Practice Patterns, Physicians', Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDA NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Opioids and benzodiazepines are commonly prescribed for cancer symptoms. In combination, they can increase the risk of adverse events, particularly for older adults with multimorbidity, who represent most patients with cancer. We aimed to understand cancer care providers' practices for opioid and benzodiazepine coprescribing and mitigating potential harms. MATERIALS AND METHODS: We interviewed oncology and palliative care providers from two health systems. Interviews focused on attitudes about and current practices for coprescribing opioids and benzodiazepines. We analyzed interview transcripts using a staged approach to thematic analysis. RESULTS: Twenty providers (10 oncology, 10 palliative care) participated. We identified three key themes. (1) Reluctance to prescribe benzodiazepines: providers reported rarely coprescribing because they do not routinely prescribe benzodiazepines, which were viewed as having a poor safety profile. (2) Medication safety precautions: these included starting at a low dose and titrating up slowly, consolidating prescriptions under one provider whenever possible, and providing patient and caregiver education around side effects, overdose, and naloxone. Compared to oncologists, palliative care providers more often described providing naloxone to patients and caregivers. (3) Risk assessment and monitoring: most providers mentioned checking state Prescription Drug Monitoring Program databases and conducting chart reviews to identify evidence of substance misuse history. Several oncologists expressed discomfort in asking about substance misuse history due to concerns about stigma. Providers described sometimes relying on their perception of a patient's trustworthiness, with some acknowledging the potential for bias. DISCUSSION: We highlight opportunities to improve medication review and reconciliation practices in oncology, increase uptake of naloxone in oncology practice, systematize efforts to screen patients for substance misuse, and strengthen integration of addiction and psychiatry services into oncology and palliative care settings. Regular use of geriatric assessment in oncology would also address many of the safety concerns we observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesAnalgesics, OpioidPractice Patterns, Physicians'NeoplasmsHumansPalliative CareAttitude of Health PersonnelFemaleMaleRisk AssessmentMedical OncologyMiddle AgedAgedAdult

Stichwörter der Autor:innen

Medication risksOncologyPalliative careQualitative studySubstance use

Substanzen

BenzodiazepinesAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States.
  • Duke University Trinity College of Arts and Sciences, Durham, NC, United States.
  • Division of Geriatrics, Duke University School of Medicine, Durham, NC, United States.
  • Department of Medicine, Duke University School of Medicine, Durham, NC, United States.
  • Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
  • Department of Pharmacy Systems, Outcomes, and Policy, University of Illinois at Chicago, Chicago, IL, United States.

Förderung

  • NHLBI NIH HHS
  • NIDA NIH HHS
  • NIA NIH HHS
  • National Institute on Aging
  • National Institute on Drug Abuse

Zitieren

APA

O'Regan, A., Lee, J. R., McDermott, C. L., Cohen, H. J., Merlin, J. S., Marais, A. D., Winn, A. N., Meghani, S. H., & Check, D. K. (2025). Opioids and benzodiazepines in oncology: Perspectives on coprescribing and mitigating risks. Journal of Geriatric Oncology. https://doi.org/10.1016/j.jgo.2024.102172

Vancouver

O'Regan A, Lee JR, McDermott CL, Cohen HJ, Merlin JS, Marais AD, et al. Opioids and benzodiazepines in oncology: Perspectives on coprescribing and mitigating risks. Journal of Geriatric Oncology. 2025. doi:10.1016/j.jgo.2024.102172

BibTeX
@article{ORegan2025,
  author = {O'Regan, Amy and Lee, Jeehye Rose and McDermott, Cara L and Cohen, Harvey Jay and Merlin, Jessica S and Marais, Andrea Des and Winn, Aaron N and Meghani, Salimah H and Check, Devon K},
  title = {Opioids and benzodiazepines in oncology: Perspectives on coprescribing and mitigating risks},
  journal = {Journal of Geriatric Oncology},
  year = {2025},
  doi = {10.1016/j.jgo.2024.102172}
}
Kostenlos starten →